Monday, May 18, 2026

Suboxone, Talc, and Depo-Provera Dockets Anchor 782-Filing Week as Toxic Tort and Sexual Misconduct Claims Expand

Federal dockets recorded 782 new mass tort filings for the week ending May 18, 2026, with pharmaceutical and consumer product MDLs commanding the bulk of volume while toxic tort and institutional misconduct dockets sustained meaningful activity.

Pharmaceutical and consumer product litigations dominated. The Suboxone Film Products Liability Litigation (MDL 3092) absorbed 265 new complaints, with Nigh Goldenberg Raso & Vaughn PLLC driving 262 of those filings in what has become one of the most firm-concentrated dockets in the federal MDL system. The Johnson & Johnson Talcum Powder Products Liability Litigation (MDL 2738) drew 110 new complaints alleging ovarian cancer and mesothelioma injuries, with Ashcraft Gerel LLP directing 70 of those actions as steering committees continued critical mediation sessions following the recent collapse of the defense's third bankruptcy attempt. The Depo-Provera Products Liability Litigation (MDL 3140) added 67 new suits asserting the contraceptive injection causes intracranial meningiomas — led by Morgan & Morgan PA and Hochman Law Firm PLLC — pushing a docket that now exceeds 5,000 total pending actions ahead of Rule 702 Daubert hearings on causation experts scheduled for late June 2026.

Toxic tort and institutional misconduct dockets also sustained volume. Hochman Law Firm PLLC managed 9 of the 18 new filings in the Paraquat Products Liability Litigation (MDL 3004). Cutter Law PC and Wagstaff Law Firm filed actions in the Uber Technologies Passenger Sexual Assault Litigation (MDL 3084), where practitioners continue to evaluate settlement matrices following sequential bellwether verdicts earlier this spring.

Practitioner Note: Counsel monitoring MDL 3092 should track the June 10, 2026 deadline for random selection of 20 core discovery pool cases. In MDL 3140, Daubert hearings for causation experts in late June will heavily dictate the trajectory of upcoming bellwethers. In MDL 2738, mediation continues following the collapse of the defense's third bankruptcy attempt — a development that has materially shifted settlement leverage toward plaintiffs' leadership.

Social Media Platforms Settle School-District Addiction Claims Ahead of Trial

On May 15, 2026, YouTube, Snap and TikTok reached settlements in the first school-district case set for trial over allegations that addictive platform design fueled youth mental-health harms and forced public schools to absorb response costs. The agreements remove three major defendants from that trial track while leaving Meta as the principal holdout facing continued exposure. For MDL 3047 practitioners, the settlements matter because the school-district claims test a damages theory distinct from individual personal-injury suits but built on the same core allegations about compulsive use, youth vulnerability and platform safety failures. The development gives plaintiffs and defendants a fresh settlement benchmark as federal social-media addiction litigation moves toward additional bellwether pressure.

Philadelphia Court of Common Pleas Filing Wrap-Up Led by Paraquat and Zantac Claims

Philadelphia Court of Common Pleas filings were concentrated in Paraquat, with 14 new cases led by Chaffin Luhana (4), Feldman & Pinto (4), Motley Rice (2), DiCello Levitt (2) and Matthews & Associates (2). Zantac added 5 filings, driven by Anapol Weiss (4) and Nachawati Law Group (1), while Roundup added 1 filing from Feldman & Pinto. The filing mix shows Philadelphia activity centered on herbicide and ranitidine claims rather than the talc narrative previously shown here, with Paraquat accounting for the clear majority of new Court of Common Pleas volume.